West Pharmaceutical Services Q2 Earnings Call Highlights

West Pharmaceutical Services beat second-quarter expectations, with revenue up 13% organically to $872 million and adjusted EPS rising 29% to $2.37, prompting the company to raise its full-year 2026 outlook. Management said the quarter benefited from strong demand in biologics, GLP-1 elastomers and high-value product components. The company’s high-value product (HVP) business was the main growth driver, with Proprietary Products up 16% organically and HVP components revenue reaching $424 million. HVP now makes up 49% of total revenue, supported by biologics, Annex 1-related upgrades and continued GLP-1 demand. West increased its full-year 2026 guidance to $3.345 billion-$3.38 billion in revenue and adjusted EPS of $8.85-$9.05, while also projecting third-quarter revenue of $820 million-$835 million. The company said margin expansion, share buybacks and recovery from a cyber incident are also supporting the improved outlook.

West Pharmaceutical Services NYSE: WST raised its full-year 2026 outlook after reporting second-quarter results that topped management’s expectations, supported by strong demand for high-value product components, biologics-related offerings and GLP-1 elastomers. Chief Executive Officer and Board Chair Eric Green said revenue reached $872 million , up 13% organically , while adjusted earnings per share rose 29% from the prior year to $2.37 . Green said the performance reflected “execution of our strategy and continued operational excellence initiatives,” as well as recovery efforts following a cyber incident during the quarter.

“Given the robust outcome in the second quarter and the ongoing momentum in the business, we are raising our guidance for full year 2026,” Green said. High-value components drive quarterly growth West’s Proprietary Products segment delivered 16% organic growth , led by the biologics market group, which rose 29% organically . The company’s high-value product, or HVP, components business generated $424 million in revenue and grew 18.4% organically , according to Chief Financial Officer Bob McMahon. Green said HVP components now account for 49% of total company revenue , up from 46% in the prior-year quarter. He pointed to three main growth drivers: biologics and biosimilars, HVP upgrades including Annex 1-related demand, and continued strength in GLP-1 elastomers. Non-GLP-1 HVP components grew in the high teens on an organic basis and were the largest contributors to the company’s outperformance in the quarter, Green said. He added that West continues to see win rates above 90% for new biologic molecules, which often require higher-quality containment products such as FluroTec and NovaPure. Management also emphasized the biosimilars opportunity. Green said biosimilar launches can expand therapy use and may allow West to maintain or increase component demand after commercialization. Annex 1 upgrades and GLP-1 demand remain key themes Green said West is seeing more customers upgrade to HVP components, often adding finishing processes such as Envision inspection. He described the Annex 1-related opportunity as being in the early stages of a multi-year transition and said it remains on track to contribute 200 basis points of revenue growth in 2026 . During the question-and-answer portion of the call, Green said West had “just shy of 800 total projects in hand” related to Annex 1 and other HVP upgrades, up 50% from the same period last year. McMahon added that the company is seeing possible “spillover” opportunities beyond Europe, including in the United